Novo Nordisk immediately introduced the presentation of 34 abstracts highlighting the breadth of its portfolio on the upcoming 84th Scientific Classes of the American Diabetes Affiliation (ADA). The convention will likely be held in-person and just about from 21–24 June 2024 in Orlando, US.
Further information from three landmark trials with semaglutide may even be introduced in devoted scientific periods. The trials assess extra potential advantages of semaglutide, together with analysis of kidney and cardiovascular endpoints in folks with kind 2 diabetes and persistent kidney illness (FLOW, semaglutide 1.0 mg) and cardiovascular and glucose-related endpoints in folks with weight problems and CVD, with and with out diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).
We acknowledge that cardiometabolic situations like heart problems, persistent kidney illness, weight problems and sort 2 diabetes are sometimes interlinked and would possibly happen in the identical affected person. We have to develop medicines that deal with a number of aspects of the illnesses. The broad information being introduced this 12 months at ADA replicate this objective. Particularly, information from FLOW and SELECT take a look at methods to deal with widespread comorbidities of diabetes and weight problems, comparable to kidney illness and heart problems.”
Stephen Gough, senior vp and international chief medical officer, Novo Nordisk
All abstracts will likely be printed on the web site of the journal Diabetes®. Information from the scientific periods will likely be made accessible after their presentation.
Abstract of displays
Scientific periods
The next information will likely be introduced within the devoted scientific periods as part of the scientific agenda of the congress:
| The primary devoted kidney final result trial with a GLP1-RA once-weekly semaglutide – FLOW trial outcomes (scientific session; 24 June, 13:30–15:00 EST) |
| SELECT trial – New appears at glycemia, irritation, and coronary heart failure (scientific session; 22 June, 08:00–09:00 EST) |
| The STEP-HFpEF and STEP-HFpEF-DM trials – Focusing on weight problems to deal with coronary heart failure (scientific session; 23 June, 16:30–18:00 EST) |
Poster and oral displays
The next abstracts have been submitted by Novo Nordisk and are accepted for presentation on the congress:
| Diabetes |
| Ozempic® (once-weekly semaglutide 1.0 mg) |
- Comparative effectiveness of semaglutide in T2D – 12 months 2 outcomes of a randomized pragmatic medical trial (230-OR)
|
- Lengthy-term effectiveness related to upkeep doses of once-weekly semaglutide in US adults with poorly managed T2D (766-P)
|
- Semaglutide in sufferers with peripheral arterial illness and sort 2 diabetes: comorbidities and concomitant medicines from the STRIDE trial (784-P)
|
- Actual-world impression of once-weekly injectable semaglutide on weight, BMI and HbA1c outcomes in kind 2 diabetes: an observational research (PAUSE) (857-P)
|
- Actual-World Influence of As soon as-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Well being Care Useful resource Utilization (HCRU) Outcomes in Sort 2 Diabetes (T2D) – An Observational Examine (PAUSE) (1884-LB)
|
| Rybelsus® (once-daily oral semaglutide) |
- Evaluating the efficacy of oral semaglutide in Chinese language sufferers with T2D by baseline traits: publish hoc evaluation of PIONEER 11 and 12 (752-P)
|
- Actual-world impression of fasting on adherence to dosing directions and efficacy of oral semaglutide throughout Ramadan in folks with kind 2 diabetes: O-SEMA-Quick sub-analysis (808-P)
|
| CagriSema |
- CagriSema improves insulin sensitivity in diet-induced overweight rats (763-P)
|
| As soon as-weekly insulin icodec |
- Healthcare useful resource utilization and prices with well timed vs delayed basal insulin initiation (816-P)
|
- Demographic, medical, and therapy traits of sufferers with well timed vs. delayed basal insulin initiation (817-P)
|
- No proof of elevated bodily activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T1D: ONWARDS 6 (824-P)
|
- Efficacy and security of once-weekly insulin icodec versus once-daily basal insulin in people with T2D by kidney perform: ONWARDS 1–5 (826-P)
|
- No proof of elevated bodily activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T2D: ONWARDS 1-5 (830-P)
|
- Adherence to app-based dose steerage for once-weekly insulin icodec in insulin-naive T2D: publish hoc evaluation of ONWARDS 5 (836-P)
|
- Influence of age on the efficacy and security of once-weekly insulin icodec versus once-daily insulin in T2D (ONWARDS 1–5) (838-P)
|
- Efficacy and security of once-weekly insulin icodec versus once-daily basal insulin in kind 2 diabetes in accordance with baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1–5 (840-P)
|
- Efficacy and security of once-weekly insulin icodec vs once-daily basal insulin in T2D by ethnicity and race: ONWARDS 1–5 (841-P)
|
- Price-effectiveness of insulin icodec for the therapy of kind 2 diabetes in Canada (1046-P)
|
- Efficacy and security outcomes with once-weekly insulin icodec versus once-daily insulin degludec in T1D in accordance with glycemic variability: ONWARDS 6 publish hoc evaluation (1882-LB)
|
| Every day insulins |
- Affect of the functionally selective insulin analog NNC-965 on cardiac construction and performance versus insulin glargine (IGla) (822-P)
|
- Improved glycemic management in folks with kind 2 diabetes (T2D) initiating or switching to insulin degludec/insulin aspart (IDegAsp) in a real-world setting in China (publication solely)
|
| Common diabetes |
- Persistence and adherence of as soon as weekly GLP-1 receptor agonists in sufferers with kind 2 diabetes and atherosclerotic heart problems in a real-world setting (740-P)
|
- Influence of newer GLP-1 RAs on HbA1c in US adults with kind 2 diabetes: a population-level time-series evaluation (774-P)
|
- Understanding attitudes about basal insulin: insights from a world survey of individuals with kind 2 diabetes (833-P)
|
|
|
- Prevalence of atherosclerotic cardiovascular illnesses in adults with kind 2 diabetes in Jordan: the PACT-MEA Examine (1789-LB)
|
- In vivo chain-splitting of human insulin (2032-LB)
|
| Digital Well being |
- Enchancment in time in vary after good insulin pen initiation in Austria (842-P)
|
- Multinational evaluation of things related to missed bolus insulin injections utilizing good pen information (843-P)
|
| Weight problems |
| Wegovy® (once-weekly semaglutide 2.4 mg) |
- CONCRETE – characterization of sufferers receiving telemedicine and branded antiobesity treatment for medical weight administration: a retrospective evaluation (1684-P)
|
- Scientific outcomes in sufferers with weight problems or chubby handled with semaglutide 2.4 mg: a real-world retrospective cohort research in the USA (SCOPE 2) (1691-P)
|
- Modeling the Influence of Semaglutide 2.4 mg in U.S. Sufferers with Atherosclerotic Cardiovascular Illness and BMI ≥27 kg/m2 (1981-LB)
|
| Common weight problems |
- Affected person-centered weight administration medical choice help: a proof-of-concept research (1101-P)
|
- Prevalence, traits, and medical burden amongst sufferers with chubby or weight problems and established ASCVD in a US actual world setting (1692-P)
|
About Ozempic®
As soon as-weekly subcutaneous semaglutide is authorised in 0.5 mg, 1.0 mg and a couple of.0 mg doses below the model identify Ozempic® and indicated as an adjunct to food regimen and train to enhance glycemic management in adults with kind 2 diabetes and to scale back the chance of main hostile cardiovascular occasions (cardiovascular loss of life, non-fatal myocardial infarction or non-fatal stroke) in adults with kind 2 diabetes and established heart problems.
About Rybelsus®
Oral semaglutide is run as soon as each day and is authorised to be used in three therapeutic doses, 3 mg, 7 mg and 14 mg below the model identify Rybelsus®. It’s indicated for the therapy of adults with insufficiently managed kind 2 diabetes mellitus to enhance glycemic management as an adjunct to food regimen and train.
About Wegovy®
As soon as-weekly subcutaneous semaglutide 2.4 mg is authorised below the model identify Wegovy® and is indicated together with a lowered calorie food regimen and elevated bodily exercise to scale back the chance of main hostile cardiovascular occasions (cardiovascular loss of life, non-fatal myocardial infarction, or non-fatal stroke) in adults with established heart problems and both weight problems or chubby, in addition to to scale back extra physique weight and preserve weight discount long run in adults and pediatric sufferers aged 12 years and older with weight problems and in adults with chubby within the presence of at the very least one weight-related comorbid situation.
